{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T04:12:55Z","timestamp":1793592775925,"version":"4.5.0"},"reference-count":235,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373274"],"award-info":[{"award-number":["82373274"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["22S21902700, 23S21900800, 23S11901300"],"award-info":[{"award-number":["22S21902700, 23S21900800, 23S11901300"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["202240370"],"award-info":[{"award-number":["202240370"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Intricate interactions between immune cells and cytokines define psoriasis, a chronic inflammatory skin condition that is immunological-mediated. Cytokines, including interleukins (ILs), interferons (IFNs), tumor necrosis factors (TNFs), chemokines, and transforming growth factor-\u03b2 (TGF-\u03b2), are essential for controlling cellular activity and immunological responses, maintaining homeostasis and contributing to the pathogenesis of psoriasis. These molecules modulate the immune microenvironment by either promoting or suppressing inflammation, which significantly impacts therapeutic outcomes. Recent research indicates that treatment strategies targeting cytokines and chemokines have significant potential, offering new approaches for regulating the immune system, inhibiting the progression of psoriasis, and reducing adverse effects of traditional therapies. This review consolidates current knowledge on cytokine and chemokine signaling pathways in psoriasis and examines their significance in treatment. Specific attention is given to cytokines like IL-17, IL-23, and TNF-\u03b1, underscoring the necessity for innovative therapies to modulate these pathways and address inflammatory processes. This review emphasizes the principal part of cytokines in the -pathological process of psoriasis and explores the challenges and opportunities they present for therapeutic intervention. Furthermore, we examine recent advancements in targeted therapies, with a particular focus on monoclonal antibodies, in ongoing research and clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1573905","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:19:59Z","timestamp":1744694399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":28,"title":["Interventions in cytokine signaling: novel horizons for psoriasis treatment"],"prefix":"10.3389","volume":"16","author":[{"given":"Lisha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyou","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongguang","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.11.024","article-title":"Nail psoriasis and nail lichen planus: Updates on diagnosis and management","volume":"90","author":"Hwang","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15867","article-title":"The genetic basis for most patients with pustular skin disease remains elusive","volume":"178","author":"Mossner","year":"2018","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.jaci.2024.05.008","article-title":"Inflammatory memory in psoriasis: From remission to recurrence","volume":"154","author":"Francis","year":"2024","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00940-8","article-title":"The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry","volume":"19","author":"Zhou","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-024-01868-3","article-title":"Targeting cytokine and chemokine signaling pathways for cancer therapy","volume":"9","author":"Yi","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-024-44886-z","article-title":"WNT-dependent interaction between inflammatory fibroblasts and FOLR2+ macrophages promotes fibrosis in chronic kidney disease","volume":"15","author":"Cohen","year":"2024","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.10.094","article-title":"CCL20 in psoriasis: A potential biomarker of disease severity, inflammation, and impaired vascular health","volume":"84","author":"Elnabawi","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"Jama"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2023.12.009","article-title":"Transdermal delivery of Fn14 siRNA using a novel composite ionic liquid for treatment of psoriasis-like skin lesions","volume":"365","author":"Li","year":"2024","journal-title":"J Control Release"},{"key":"B13","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jaci.2022.03.028","article-title":"Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions","volume":"150","author":"Adachi","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202004433","article-title":"Cytokines: from clinical significance to quantification","volume":"8","author":"Liu","year":"2021","journal-title":"Adv Sci (Weinh)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41421-020-0167-x","article-title":"Inflammasome activation and regulation: toward a better understanding of complex mechanisms","volume":"6","author":"Zheng","year":"2020","journal-title":"Cell Discovery"},{"key":"B17","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","article-title":"The cytokine mediated molecular pathophysiology of psoriasis and its clinical implications","volume":"22","author":"Singh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110338","article-title":"Oxidized low-density lipoprotein regulates macrophage polarization in atherosclerosis","volume":"120","author":"He","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41419-024-06463-6","article-title":"The implications of FASN in immune cell biology and related diseases","volume":"15","author":"Xiao","year":"2024","journal-title":"Cell Death Dis"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3159","article-title":"PPAR\u03b3 signaling and metabolism: the good, the bad and the future","volume":"19","author":"Ahmadian","year":"2013","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115586","article-title":"SCD1 is the critical signaling hub to mediate metabolic diseases: Mechanism and the development of its inhibitors","volume":"170","author":"Sun","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.107037","article-title":"SIRT1\/SREBPs-mediated regulation of lipid metabolism","volume":"199","author":"Shen","year":"2024","journal-title":"Pharmacol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2022.102389","article-title":"Signal amplification in the KEAP1-NRF2-ARE antioxidant response pathway","volume":"54","author":"Liu","year":"2022","journal-title":"Redox Biol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12974-025-03363-0","article-title":"Mitochondrial DNA leakage: underlying mechanisms and therapeutic implications in neurological disorders","volume":"22","author":"Zhang","year":"2025","journal-title":"J Neuroinflamm"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/all.16378","article-title":"The influence of lifestyle and environmental factors on host resilience through a homeostatic skin microbiota: An EAACI Task Force Report","volume":"79","author":"Kortekaas Krohn","year":"2024","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/microorganisms13010023","article-title":"Probiotic Bacterium-Derived p40, p75, and HM0539 Proteins as Novel Postbiotics and Gut-Associated Immune System (GAIS) Modulation: Postbiotic-Gut-Health Axis","volume":"13","author":"Bing\u00f6l","year":"2024","journal-title":"Microorganisms"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature06246","article-title":"Recognition of microorganisms and activation of the immune response","volume":"449","author":"Medzhitov","year":"2007","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.bbi.2023.12.005","article-title":"Role of stress in skin diseases: A neuroendocrine-immune interaction view","volume":"116","author":"Zhang","year":"2024","journal-title":"Brain Behav Immun"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14071","article-title":"Role of neuroimmune circuits and pruritus in psoriasis","volume":"29","author":"Ayasse","year":"2020","journal-title":"Exp Dermatol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"Cd011541","DOI":"10.1002\/14651858.CD011541.pub2","article-title":"Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis","volume":"4","author":"Maruani","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-cw1 and psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01488","article-title":"CLA(+) T cell response to microbes in psoriasis","volume":"9","author":"De-Jes\u00fas-Gil","year":"2018","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1365-2133.2010.09742.x","article-title":"Foxp3+ regulatory T cells and related cytokines differentially expressed in plaque vs. guttate psoriasis vulgaris","volume":"163","author":"Yan","year":"2010","journal-title":"Br J Dermatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2018.07.001","article-title":"The distinct role and regulatory mechanism of IL-17 and IFN-\u03b3 in the initiation and development of plaque vs guttate psoriasis","volume":"92","author":"Yan","year":"2018","journal-title":"J Dermatol Sci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.jid.2019.12.022","article-title":"Specific igA and CLA(+) T-cell IL-17 response to streptococcus pyogenes in psoriasis","volume":"140","author":"De-Jes\u00fas-Gil","year":"2020","journal-title":"J Invest Dermatol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.jaci.2016.02.008","article-title":"Streptococcus pyogenes-induced cutaneous lymphocyte antigen-positive T cell-dependent epidermal cell activation triggers TH17 responses in patients with guttate psoriasis","volume":"138","author":"Ruiz-Romeu","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.08.048","article-title":"Microbe-dependent induction of IL-9 by CLA(+) T cells in psoriasis and relationship with IL-17A","volume":"138","author":"Ruiz-Romeu","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.09.080","article-title":"Generalized pustular psoriasis: A consensus statement from the National Psoriasis Foundation","volume":"90","author":"Armstrong","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18720","article-title":"Prevalence, comorbidities and mortality of generalized pustular psoriasis: A literature review","volume":"37","author":"Prinz","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0519-3","article-title":"Autoinflammatory psoriasis\u201d-genetics and biology of pustular psoriasis","volume":"18","author":"Uppala","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13614","article-title":"Treatment of two patients with generalized pustular psoriasis with the interleukin-1\u03b2 inhibitor gevokizumab","volume":"173","author":"Mansouri","year":"2015","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2023-0061","article-title":"Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-1 study): a plain language summary","volume":"15","author":"Armstrong","year":"2023","journal-title":"Immunotherapy"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18245","article-title":"Management of psoriasis as a systemic disease: what is the evidence","volume":"182","author":"Korman","year":"2020","journal-title":"Br J Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00766-z","article-title":"Resolution of plaque-type psoriasis: what is left behind (and reinitiates the disease)","volume":"41","author":"Benezeder","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13800","article-title":"Interleukin 23p19 inhibitors in chronic plaque psoriasis with focus on mirikizumab: A narrative review","volume":"33","author":"Salimi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1341708","article-title":"Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses - IL PSO (Italian landscape psoriasis)","volume":"14","author":"Gargiulo","year":"2023","journal-title":"Front Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad283","article-title":"Integrative serum proteomics analysis reveals distinct immune and cardiovascular profile dysregulation in erythrodermic psoriasis","volume":"189","author":"Song","year":"2023","journal-title":"Br J Dermatol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01283-2","article-title":"Targeted treatment for erythrodermic psoriasis: rationale and recent advances","volume":"80","author":"Shao","year":"2020","journal-title":"Drugs"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0175-0","article-title":"Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition","volume":"15","author":"Scher","year":"2019","journal-title":"Nat Rev Rheumatol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.06.006","article-title":"Axial involvement in psoriatic arthritis: An update for rheumatologists","volume":"51","author":"Poddubnyy","year":"2021","journal-title":"Semin Arthritis Rheum"},{"key":"B57","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jaad.2020.05.089","article-title":"Axial psoriatic arthritis: An update for dermatologists","volume":"84","author":"Gottlieb","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/nature14175","article-title":"Clinical improvement in psoriasis with specific targeting of interleukin-23","volume":"521","author":"Kopp","year":"2015","journal-title":"Nature"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2019.03.011","article-title":"The immunobiology of the interleukin-12 family: room for discovery","volume":"50","author":"Tait Wojno","year":"2019","journal-title":"Immunity"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3895","article-title":"IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases","volume":"21","author":"Teng","year":"2015","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.113928","article-title":"New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers","volume":"175","author":"Chyuan","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20030451","article-title":"Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris","volume":"199","author":"Lee","year":"2004","journal-title":"J Exp Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.11.012","article-title":"T cell responses in psoriasis and psoriatic arthritis","volume":"14","author":"Diani","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B65","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.tips.2014.07.006","article-title":"Targeting Th17 cells in autoimmune diseases","volume":"35","author":"Yang","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788940","article-title":"The role of helper T cells in psoriasis","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2012.11.005","article-title":"The IL-23\/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses","volume":"34","author":"Lowes","year":"2013","journal-title":"Trends Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13581","article-title":"Monocyte-derived inflammatory Langerhans cells and dermal dendritic cells mediate psoriasis-like inflammation","volume":"7","author":"Singh","year":"2016","journal-title":"Nat Commun"},{"key":"B71","doi-asserted-by":"publisher","first-page":"5310","DOI":"10.1038\/s41598-019-41655-7","article-title":"Monocytes\/Macrophages play a pathogenic role in IL-23 mediated psoriasis-like skin inflammation","volume":"9","author":"Wang","year":"2019","journal-title":"Sci Rep"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.3.1141","article-title":"Overexpression of vascular permeability factor\/vascular endothelial growth factor and its receptors in psoriasis","volume":"180","author":"Detmar","year":"1994","journal-title":"J Exp Med"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0907550106","article-title":"Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis","volume":"106","author":"Schonthaler","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-12-3793","article-title":"Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis","volume":"102","author":"Xia","year":"2003","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2010.03.023","article-title":"Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis\u2013a possible target for novel therapies","volume":"58","author":"Canavese","year":"2010","journal-title":"J Dermatol Sci"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi8823","article-title":"TWEAK functions with TNF and IL-17 on keratinocytes and is a potential target for psoriasis therapy","volume":"6","author":"Gupta","year":"2021","journal-title":"Sci Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2021.1964420","article-title":"A non-clinical comparative study of IL-23 antibodies in psoriasis","volume":"13","author":"Zhou","year":"2021","journal-title":"MAbs"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01682","article-title":"The IL-17 family of cytokines in psoriasis: IL-17A and beyond","volume":"9","author":"Brembilla","year":"2018","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI93396","article-title":"Clinically resolved psoriatic lesions contain psoriasis-specific IL-17-producing alphabeta T cell clones","volume":"127","author":"Matos","year":"2017","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","first-page":"a028522","DOI":"10.1101\/cshperspect.a028522","article-title":"Interleukin 17 family cytokines: signaling mechanisms, biological activities, and therapeutic implications","volume":"10","author":"Monin","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-012-8307-1","article-title":"Role of IL-17 in psoriasis and psoriatic arthritis","volume":"44","author":"Raychaudhuri","year":"2013","journal-title":"Clin Rev Allergy Immunol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40257-015-0162-4","article-title":"Anti-IL-17 medications used in the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"17","author":"Canavan","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2019.01.006","article-title":"Imiquimod-induced psoriasis in mice depends on the IL-17 signaling of keratinocytes","volume":"139","author":"Moos","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.65","article-title":"Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis","volume":"129","author":"Harper","year":"2009","journal-title":"J Invest Dermatol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3390\/ijms21041275","article-title":"Interleukin-17A and keratinocytes in psoriasis","volume":"21","author":"Furue","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1016\/j.jid.2019.01.014","article-title":"IL-17 and IL-22 promote keratinocyte stemness in the germinative compartment in psoriasis","volume":"139","author":"Ekman","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2514","article-title":"An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target","volume":"9","author":"Mahil","year":"2017","journal-title":"Sci Transl Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1201505","article-title":"Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation","volume":"190","author":"Johnston","year":"2013","journal-title":"J Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00200","article-title":"IL-36gamma is a strong inducer of IL-23 in psoriatic cells and activates angiogenesis","volume":"9","author":"Bridgewood","year":"2018","journal-title":"Front Immunol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/s0092-8674(01)00187-8","article-title":"Interleukin 20: discovery, receptor identification, and role in epidermal function","volume":"104","author":"Blumberg","year":"2001","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-009-0457-0","article-title":"IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not","volume":"87","author":"Wolk","year":"2009","journal-title":"J Mol Med (Berl)"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1111\/j.1610-0387.2011.07611.x","article-title":"Research in practice: IL-22 and IL-20: significance for epithelial homeostasis and psoriasis pathogenesis","volume":"9","author":"Sabat","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2014.308","article-title":"IL-19 is a component of the pathogenetic IL-23\/IL-17 cascade in psoriasis","volume":"134","author":"Witte","year":"2014","journal-title":"J Invest Dermatol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.719562","article-title":"Interleukin-17A drives IL-19 and IL-24 expression in skin stromal cells regulating keratinocyte proliferation","volume":"12","author":"Xu","year":"2021","journal-title":"Front Immunol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/nri2586","article-title":"Structure and signalling in the IL-17 receptor family","volume":"9","author":"Gaffen","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.immuni.2019.03.021","article-title":"The IL-17 family of cytokines in health and disease","volume":"50","author":"McGeachy","year":"2019","journal-title":"Immunity"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.3390\/pharmaceutics13071064","article-title":"Therapeutic development based on the immunopathogenic mechanisms of psoriasis","volume":"13","author":"Tseng","year":"2021","journal-title":"Pharmaceutics"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1509971112","article-title":"IkappaBzeta is a key driver in the development of psoriasis","volume":"112","author":"Johansen","year":"2015","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-019-00742-7","article-title":"T cell pathology in skin inflammation","volume":"41","author":"Sabat","year":"2019","journal-title":"Semin Immunopathol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-024-08991-7","article-title":"The immunology of psoriasis-current concepts in pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin Rev Allergy Immunol"},{"key":"B104","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.autrev.2014.01.050","article-title":"The IL-23\/IL-17 axis in psoriatic arthritis","volume":"13","author":"Suzuki","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15533","article-title":"Interleukin (IL)-17A and IL-22-producing neutrophils in psoriatic skin","volume":"177","author":"Dyring-Andersen","year":"2017","journal-title":"Br J Dermatol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20231425","article-title":"CXCL12+ dermal fibroblasts promote neutrophil recruitment and host defense by recognition of IL-17","volume":"221","author":"Cavagnero","year":"2024","journal-title":"J Exp Med"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B108","doi-asserted-by":"publisher","first-page":"555","DOI":"10.3390\/ijms23010555","article-title":"IL-17 pathway members as potential biomarkers of effective systemic treatment and cardiovascular disease in patients with moderate-to-severe psoriasis","volume":"23","author":"Wang","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20090","article-title":"Signalling of multiple interleukin (IL)-17 family cytokines via IL-17 receptor A drives psoriasis-related inflammatory pathways","volume":"185","author":"Tollenaere","year":"2021","journal-title":"Br J Dermatol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-023-00856-y","article-title":"Targeting IL-6 trans-signalling: past, present and future prospects","volume":"23","author":"Rose-John","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 receptor system and its role in physiological and pathological conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin Sci (Lond)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190347","article-title":"Historical overview of the interleukin-6 family cytokine","volume":"217","author":"Kang","year":"2020","journal-title":"J Exp Med"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.11.022","article-title":"IL-6 differs from TNF-alpha: unpredicted clinical effects caused by IL-6 blockade in psoriasis","volume":"137","author":"Blauvelt","year":"2017","journal-title":"J Invest Dermatol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jep.2023.116809","article-title":"Qinzhu Liangxue inhibits IL-6-induced hyperproliferation and inflammation in HaCaT cells by regulating METTL14\/SOCS3\/STAT3 axis","volume":"317","author":"Chen","year":"2023","journal-title":"J Ethnopharmacol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","article-title":"Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies","volume":"181","author":"Maddur","year":"2012","journal-title":"Am J Pathol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"566","DOI":"10.3390\/antiox8110566","article-title":"Fibroblasts to keratinocytes redox signaling: the possible role of ROS in psoriatic plaque formation","volume":"8","author":"Barygina","year":"2019","journal-title":"Antioxid (Basel)"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/ni1391","article-title":"Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease","volume":"7","author":"Veldhoen","year":"2006","journal-title":"Nat Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"B123","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4344","DOI":"10.3390\/ijms22094344","article-title":"Exploring the role of IL-36 cytokines as a new target in psoriatic disease","volume":"22","author":"Iznardo","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0467-1","article-title":"IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease","volume":"20","author":"Hojen","year":"2019","journal-title":"Nat Immunol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.phymed.2022.154384","article-title":"Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis","volume":"105","author":"Hu","year":"2022","journal-title":"Phytomedicine"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaad.2023.02.040","article-title":"Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","volume":"89","author":"Elewski","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4(+) T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.11.009","article-title":"Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets","volume":"105","author":"Akiyama","year":"2022","journal-title":"J Dermatol Sci"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01339-3","article-title":"IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation","volume":"23","author":"Ni","year":"2022","journal-title":"Nat Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/s1359-6101(03)00002-9","article-title":"Interleukin-17 family and IL-17 receptors","volume":"14","author":"Moseley","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aax1686","article-title":"Enhanced IL-36R signaling promotes barrier impairment and inflammation in skin and intestine","volume":"5","author":"Hovhannisyan","year":"2020","journal-title":"Sci Immunol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.732790","article-title":"The pathological mechanism and potential application of IL-38 in autoimmune diseases","volume":"12","author":"Han","year":"2021","journal-title":"Front Pharmacol"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3390\/ijms20061257","article-title":"IL-36, IL-37, and IL-38 cytokines in skin and joint inflammation: A comprehensive review of their therapeutic potential","volume":"20","author":"Boutet","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20963","article-title":"The biological basis of disease recurrence in psoriasis: a historical perspective and current models","volume":"186","author":"Puig","year":"2022","journal-title":"Br J Dermatol"},{"key":"B138","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2018.01.001","article-title":"The enigmatic role of IL-38 in inflammatory diseases","volume":"39","author":"Garraud","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2011.01.006","article-title":"Regulating Il9 transcription in T helper cells","volume":"32","author":"Perumal","year":"2011","journal-title":"Trends Immunol"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1111\/ced.14335","article-title":"Interleukin-9 serves as a key link between systemic inflammation and angiogenesis in psoriasis","volume":"46","author":"Midde","year":"2021","journal-title":"Clin Exp Dermatol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1002\/art.39649","article-title":"Interleukin-9 overexpression and th9 polarization characterize the inflamed gut, the synovial tissue, and the peripheral blood of patients with psoriatic arthritis","volume":"68","author":"Ciccia","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B142","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41577-020-0396-0","article-title":"IL-9-producing T cells: potential players in allergy and cancer","volume":"21","author":"Angkasekwinai","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri3824","article-title":"The development and in vivo function of T helper 9 cells","volume":"15","author":"Kaplan","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"B144","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1016\/j.jid.2022.06.021","article-title":"Functional interplay between IL-9 and peptide YY contributes to chronic skin inflammation","volume":"142","author":"Kamiya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216224","article-title":"PDE4D\/cAMP\/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes","volume":"565","author":"Feng","year":"2023","journal-title":"Cancer Lett"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3347","article-title":"Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid","volume":"17","author":"Jin","year":"2016","journal-title":"Nat Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R","volume":"168","author":"Parham","year":"2002","journal-title":"J Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00211.x","article-title":"Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4","volume":"202","author":"Watford","year":"2004","journal-title":"Immunol Rev"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/ni1016-1235c","article-title":"Erratum: CD69 controls the uptake of L-tryptophan through LAT1-CD98 and AhR-dependent secretion of IL-22 in psoriasis","volume":"17","author":"Cibrian","year":"2016","journal-title":"Nat Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08769.x","article-title":"Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways","volume":"159","author":"Nograles","year":"2008","journal-title":"Br J Dermatol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2134","article-title":"Transcription factor c-Maf mediates the TGF-beta-dependent suppression of IL-22 production in T(H)17 cells","volume":"12","author":"Rutz","year":"2011","journal-title":"Nat Immunol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M007837200","article-title":"Identification of the functional interleukin-22 (IL-22) receptor complex: the IL-10R2 chain (IL-10Rbeta) is a common chain of both the IL-10 and IL-22 (IL-10-related T cell-derived inducible factor, IL-TIF) receptor complexes","volume":"276","author":"Kotenko","year":"2001","journal-title":"J Biol Chem"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.6.3695","article-title":"IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes","volume":"174","author":"Boniface","year":"2005","journal-title":"J Immunol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.178.4.2229","article-title":"The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis","volume":"178","author":"Sa","year":"2007","journal-title":"J Immunol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.170291697","article-title":"Human interleukin-10-related T cell-derived inducible factor: molecular cloning and functional characterization as an hepatocyte-stimulating factor","volume":"97","author":"Dumoutier","year":"2000","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1747.2003.12626.x","article-title":"Epidermal overexpression of interleukin-19 and -20 mRNA in psoriatic skin disappears after short-term treatment with cyclosporine a or calcipotriol","volume":"121","author":"Romer","year":"2003","journal-title":"J Invest Dermatol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1600-0625.2006.00516.x","article-title":"Interleukin (IL)-19, IL-20 and IL-24 are produced by and act on keratinocytes and are distinct from classical ILs","volume":"15","author":"Kunz","year":"2006","journal-title":"Exp Dermatol"},{"key":"B159","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/nrd4176","article-title":"Therapeutic opportunities of the IL-22-IL-22R1 system","volume":"13","author":"Sabat","year":"2014","journal-title":"Nat Rev Drug Discovery"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF\u2013a primary mediator of the host response","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"B161","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/14728222.2019.1586886","article-title":"Tumor necrosis factor receptor-2 (TNFR2): an overview of an emerging drug target","volume":"23","author":"Medler","year":"2019","journal-title":"Expert Opin Ther Targets"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-01002-7","article-title":"TNF and TNF receptors as therapeutic targets for rheumatic diseases and beyond","volume":"19","author":"Siegmund","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.607","article-title":"Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75","volume":"181","author":"Sheehan","year":"1995","journal-title":"J Exp Med"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.00401","article-title":"Selective targeting of TNF receptors as a novel therapeutic approach","volume":"8","author":"Fischer","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"B167","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/jcm12041630","article-title":"Past, present and (Foreseeable) future of biological anti-TNF alpha therapy","volume":"12","author":"Leone","year":"2023","journal-title":"J Clin Med"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113683","article-title":"Role of interferon-gamma (IFN-\u03b3) and IFN-\u03b3 receptor 1\/2 (IFN\u03b3R1\/2) in regulation of immunity, infection, and cancer development: IFN-\u03b3-dependent or independent pathway","volume":"155","author":"Ding","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2020.108513","article-title":"Psoriatic arthritis under the influence of IFN\u03b3","volume":"218","author":"Dai","year":"2020","journal-title":"Clin Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2022.10.025","article-title":"Skin IL-17A and IFN-\u03b3 Production correlate with disease severity in patients with psoriasis and streptococcal infection","volume":"143","author":"Della Bella","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B172","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jid.2022.05.1094","article-title":"Comparison of the inflammatory circuits in psoriasis vulgaris, non\u2013Pustular palmoplantar psoriasis, and palmoplantar pustular psoriasis","volume":"143","author":"Wang","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.12.657","article-title":"Cross-talk between IFN-\u03b3 and TWEAK through miR-149 amplifies skin inflammation in psoriasis","volume":"147","author":"Srivastava","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2001310","article-title":"IFN-\u03b3 Drives human monocyte differentiation into highly proinflammatory macrophages that resemble a phenotype relevant to psoriasis","volume":"207","author":"Luque-Martin","year":"2021","journal-title":"J Immunol"},{"key":"B175","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1038\/s41467-021-24785-3","article-title":"3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine","volume":"12","author":"Clement","year":"2021","journal-title":"Nat Commun"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109585","article-title":"Kaempferol modulates IFN-\u03b3 induced JAK-STAT signaling pathway and ameliorates imiquimod-induced psoriasis-like skin lesions","volume":"114","author":"Li","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106070","article-title":"Effects of luteolin on treatment of psoriasis by repressing HSP90","volume":"79","author":"Lv","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B178","doi-asserted-by":"publisher","first-page":"a021873","DOI":"10.1101\/cshperspect.a021873","article-title":"TGF-\u03b2 and the TGF-\u03b2 Family: context-dependent roles in cell and tissue physiology","volume":"8","author":"Morikawa","year":"2016","journal-title":"Cold Spring Harbor Perspect Biol"},{"key":"B179","doi-asserted-by":"publisher","first-page":"121650","DOI":"10.1016\/j.lfs.2023.121650","article-title":"The role of GDF11 during inflammation \u2013 An overview","volume":"322","author":"Machelak","year":"2023","journal-title":"Life Sci"},{"key":"B180","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.3390\/ijms241210132","article-title":"IL-6 and TGF-\u03b2-secreting adoptively-transferred murine mesenchymal stromal cells accelerate healing of psoriasis-like skin inflammation and upregulate IL-17A and TGF-\u03b2","volume":"24","author":"Cuesta-Gomez","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/path.5178","article-title":"Keratin 17 in disease pathogenesis: from cancer to dermatoses","volume":"247","author":"Yang","year":"2018","journal-title":"J Pathol"},{"key":"B182","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jid.2022.07.026","article-title":"Decreasing GDF15 promotes inflammatory signals and neutrophil infiltration in psoriasis models","volume":"143","author":"Zhang","year":"2023","journal-title":"J Invest Dermatol"},{"key":"B183","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00976","article-title":"CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond","volume":"11","author":"Karin","year":"2020","journal-title":"Front Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C\u2013X\u2013C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.11.007","article-title":"CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - A target for novel cancer therapy","volume":"63","author":"Tokunaga","year":"2018","journal-title":"Cancer Treat Rev"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.818173","article-title":"Estrogen acts through estrogen receptor-\u03b2 to promote mannan-induced psoriasis-like skin inflammation","volume":"13","author":"Wu","year":"2022","journal-title":"Front Immunol"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.030791","article-title":"Psoriasis treatment: traditional therapy","author":"Lebwohl","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20131917","article-title":"Counter-regulation of T cell effector function by differentially activated p38","volume":"211","author":"Alam","year":"2014","journal-title":"J Exp Med"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1172\/jci1165","article-title":"Sunlight-induced basal cell carcinoma tumor cells and ultraviolet-B-irradiated psoriatic plaques express Fas ligand (CD95L)","volume":"101","author":"Gutierrez-Steil","year":"1998","journal-title":"J Clin Invest"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/nri3045","article-title":"Modulation of the immune system by UV radiation: more than just the effects of vitamin D","volume":"11","author":"Hart","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.9b15668","article-title":"Hyaluronic acid-based dissolving microneedle patch loaded with methotrexate for improved treatment of psoriasis","volume":"11","author":"Du","year":"2019","journal-title":"ACS Appl Mater Interf"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1111\/cod.14639","article-title":"A re-assessment of the value of markers of corticosteroid contact allergy in the Spanish baseline series: Clobetasol propionate in the spotlight","volume":"91","author":"Mercader-Garc\u00eda","year":"2024","journal-title":"Contact Dermatitis"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1172\/jci28034","article-title":"Macrophages and neutrophils are the targets for immune suppression by glucocorticoids in contact allergy","volume":"117","author":"Tuckermann","year":"2007","journal-title":"J Clin Invest"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.4183\/aeb.2016.232","article-title":"Topical steroid induced facial rosaceiform dermatitis","volume":"12","author":"Tatu","year":"2016","journal-title":"Acta Endocrinol (Buchar)"},{"key":"B198","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New treatment addressing the pathogenesis of psoriasis","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac500","article-title":"Comparative effectiveness of guselkumab in psoriatic arthritis: updates to a systematic literature review and network meta-analysis","volume":"62","author":"Mease","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002873","article-title":"Tildrakizumab for moderate-to-severe plaque psoriasis in Chinese patients: A 12-week randomized placebo-controlled phase III trial with long-term extension","volume":"137","author":"Yu","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18010","article-title":"Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis","volume":"36","author":"Gooderham","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B204","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1016\/s2665-9913(23)00120-0","article-title":"Safety and efficacy of mirikizumab versus secukinumab and placebo in the treatment of moderate-to-severe plaque psoriasis (OASIS-2): a phase 3, multicentre, randomised, double-blind study","volume":"5","author":"Papp","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19262","article-title":"Secukinumab shows high and sustained efficacy in nail psoriasis: 2.5-year results from the randomized placebo-controlled TRANSFIGURE study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"B209","doi-asserted-by":"publisher","first-page":"14904","DOI":"10.3390\/ijms232314904","article-title":"Two epitope regions revealed in the complex of IL-17A and anti-IL-17A V(H)H domain","volume":"23","author":"Kostareva","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.19974","article-title":"Management of moderate to severe psoriasis with brodalumab-Real-world evidence from the LIBERO study","volume":"38","author":"von Kiedrowski","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"B213","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.cytogfr.2014.10.009","article-title":"An inflammatory triangle in psoriasis: TNF, type I IFNs and IL-17","volume":"26","author":"Grine","year":"2015","journal-title":"Cytokine Growth Factor Rev"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02746","article-title":"Psoriasis: classical vs. Paradoxical. The yin-yang of TNF and type I interferon","volume":"9","author":"Mylonas","year":"2018","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.02.002","article-title":"and B as potent antipsoriatics: Tumor necrosis factor-\u03b1 inhibitors with unprecedented chemical architectures","volume":"14","author":"Duan","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B216","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.3390\/life13051076","article-title":"Niosomal curcumin suppresses IL17\/IL23 immunopathogenic axis in skin lesions of psoriatic patients: A pilot randomized controlled trial","volume":"13","author":"Kolahdooz","year":"2023","journal-title":"Life (Basel)"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2023.08.010","article-title":"Response to anti-IL17 therapy in inflammatory disease is not strongly impacted by genetic background","volume":"110","author":"Zhang","year":"2023","journal-title":"Am J Hum Genet"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.2147\/jir.S468746","article-title":"Investigation and confirmation of PYCARD as a potential biomarker for the management of psoriasis disease","volume":"17","author":"Xu","year":"2024","journal-title":"J Inflammation Res"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-203037","article-title":"Biomarkers in psoriasis and psoriatic arthritis","author":"Villanova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.02.009","article-title":"Cardiovascular risk in patients with psoriasis: JACC review topic of the week","volume":"77","author":"Garshick","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1002\/art.42921","article-title":"Phase 2 trial of deucravacitinib in psoriatic arthritis: biomarkers associated with disease activity, pharmacodynamics, and clinical responses","volume":"76","author":"FitzGerald","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201697","article-title":"Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab","volume":"72","author":"Wagner","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00364","article-title":"IL33: roles in allergic inflammation and therapeutic perspectives","volume":"10","author":"Chan","year":"2019","journal-title":"Front Immunol"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2021.174431","article-title":"Curcumin alleviates imiquimod-induced psoriasis in progranulin-knockout mice","volume":"909","author":"Zhou","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1038\/nature09978","article-title":"Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing ROR\u03b3t activity","volume":"472","author":"Huh","year":"2011","journal-title":"Nature"},{"key":"B227","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3390\/pharmaceutics15010229","article-title":"Curcumin-based nanomedicines in the treatment of inflammatory and immunomodulated diseases: an evidence-based comprehensive review","volume":"15","author":"Laurindo","year":"2023","journal-title":"Pharmaceutics"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adi2848","article-title":"A single-cell atlas of IL-23 inhibition in cutaneous psoriasis distinguishes clinical response","volume":"9","author":"Wu","year":"2024","journal-title":"Sci Immunol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N Engl J Med"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017160","article-title":"The IL23R R381Q gene variant protects against immune-mediated diseases by impairing IL-23-induced Th17 effector response in humans","volume":"6","author":"Meglio","year":"2011","journal-title":"PloS One"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103735","article-title":"T lymphocyte plasticity in chronic inflammatory diseases: The emerging role of the Ikaros family as a key Th17-Treg switch","volume":"24","author":"Ram\u00f3n-V\u00e1zquez","year":"2025","journal-title":"Autoimmun Rev"},{"key":"B233","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3390\/ijms22083998","article-title":"Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis","volume":"22","author":"Olejniczak-Staruch","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B234","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.3390\/nu14142970","article-title":"Gut microbiota in psoriasis","volume":"14","author":"Buha\u015f","year":"2022","journal-title":"Nutrients"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113388","article-title":"Current therapeutic overview and future perspectives regarding the treatment of psoriasis","volume":"143","author":"Ferrara","year":"2024","journal-title":"Int Immunopharmacol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:20:07Z","timestamp":1744694407000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1573905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":235,"alternative-id":["10.3389\/fimmu.2025.1573905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1573905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1573905"}}